StockData
Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc. (COAG) stock

COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)

Close on Nov 17, 2026Market cap $1.82BP/E –Yield –

Hemab Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Hemab Therapeutics

Hemab Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Hemab Therapeutics figures

See a number that looks wrong?